Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Continuous Intraocular Pressure (IOP) Measurement During Glaucoma Drainage Device Implantation

Gouws, Pieter MBChB, FRCOphth; Moss, Edward B. BSc; Trope, Graham E. PhD, MB, FRCSC; Ross Ethier, C. PhD

doi: 10.1097/IJG.0b013e3180391a5d
Original Studies
Buy

Purpose To measure the effect of the implantation of a glaucoma drainage device on the intraocular pressure (IOP) during the implantation surgery.

Method We implanted telemetry devices into 1 eye each of 3 white New Zealand rabbits. Once the telemetry was found to be working and the rabbits had fully recovered from surgery, we implanted a glaucoma drainage device into the same eye while continually monitoring the IOP with the telemetry devices.

Results During surgery IOP was extremely variable, however, extremely high pressures were recorded in association with suturing and viscoelastic injection.

Discussion The fact that pressures are significantly raised during some surgical events should make surgeons aware that manipulations need to be kept as short as possible to prevent further potential damage to glaucomatous optic nerves. There is a possibility of dramatically raising the IOP during surgery, specifically in complicated cases requiring prolonged manipulation and/or forcible deepening of the anterior chamber. In such cases, it may be a good idea to time the duration of manipulations to prevent prolonged episodes of elevated IOP.

*Department of Ophthalmology, Conquest Hospital, Hastings, UK

Department of Ophthalmology and Vision Sciences

Institute for Biomaterials and Biomedical Engineering

§Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, Ontario, Canada

Supported financially by the Canadian Institutes of Health Research though the POP program (C.R.E.) and by Physicians Service Incorporated Foundation (G.E.T., C.R.E.).

Reprints: C. Ross Ethier, PhD, Institute of Biomaterials and Biomedical Engineering, 164 College St, University of Toronto, Toronto, Ontario M5S 3G9, Canada (e-mail: ethier@mie.utoronto).

Received for publication September 24, 2006; accepted January 17, 2007

Proprietary Interest: CRE holds a patent on the GDD implanted in this study.

Copyright © 2007 Wolters Kluwer Health, Inc. All rights reserved.